Timing clarification: Clorox is reporting today, Monday, August 3, 2026—not tomorrow. Results and prepared remarks are scheduled for 4:15 p.m. ET, followed by the earnings call at 5:00 p.m. ET. (investors.thecloroxcompany.com)
This report is less about whether Clorox lands a few cents above or below quarterly consensus and more about whether management can establish a credible fiscal 2027 recovery path.
Fiscal Q4 faces unusually difficult comparisons, acquisition accounting and commodity pressure. Accordingly, weak year-over-year sales, earnings and gross-margin figures are already expected. The more important questions are:
A quarter roughly in line with consensus could be received positively if management offers a credible margin-recovery framework. Conversely, an EPS beat driven by reduced advertising or other discretionary spending would be lower quality if market-share trends remain weak.
Available consensus estimates point to approximately:
| Fiscal Q4 2026 | Expectation |
|---|---|
| Revenue | $1.91 billion |
| Adjusted EPS | $1.64 |
The consensus figures are close to what is implied by Clorox’s full-year guidance. Analysts expect approximately $1.914 billion in revenue and $1.64 of EPS. (tipranks.com)
After Q3, Clorox guided to:
Clorox had generated $3.47 of GAAP EPS and approximately $3.88 of adjusted EPS through the first nine months. That implies the following Q4 ranges:
| Implied Q4 from FY guidance | Range |
|---|---|
| GAAP EPS | $1.31–$1.51 |
| Adjusted EPS | $1.57–$1.77 |
| Approximate revenue | $1.90 billion |
Thus, consensus sits near the middle of the adjusted-EPS range and very close to the revenue implied by guidance. The principal risk is not necessarily a Q4 miss; it is an FY2027 outlook that suggests the current cost and market-share problems will persist.
Clorox’s underlying Q4 sales performance will be obscured by two major items:
Ahead of last year’s ERP conversion, retailers built approximately two weeks of inventory. That inflated fiscal Q4 2025 shipments and subsequently depressed fiscal 2026 shipments as retailers worked through the inventory.
Management estimates that this dynamic reduced FY2026 sales growth by approximately 7.5 percentage points and adjusted EPS by about $0.90. This is a comparison issue rather than a fresh deterioration in end demand, but it makes reported growth difficult to interpret. (investors.thecloroxcompany.com)
Investors should focus on:
Clorox completed the GOJO acquisition on April 1, adding Purell and GOJO’s professional health-and-hygiene business. Q4 therefore includes the first full quarter of GOJO results. (investors.thecloroxcompany.com)
Management previously expected GOJO to contribute approximately:
Reported revenue near $1.9 billion would therefore still imply a sharp decline in the legacy business against the ERP-inflated comparison. Investors should not mistake the GOJO contribution for an organic acceleration.
Management indicated that Q4 gross margin could decline approximately 500 basis points year over year. The main components are:
A large portion of the decline is therefore temporary or acquisition-accounting related. However, investors need to separate those effects from the underlying trajectory.
A constructive report would show:
The concern is that management entered Q4 assuming oil of roughly $100 per barrel and estimated a $20–$25 million quarterly headwind, before meaningful mitigation. If that cost environment persists, the annualized exposure could be significant—particularly for Glad, given its resin sensitivity.
Cleaning was one of the stronger areas entering Q4. Clorox PURE and scent-oriented innovation were reportedly performing well, and the company had continued gaining share despite a competitive promotional environment.
The main questions are:
Management has described GOJO as an approximately $800 million business, largely B2B, with EBITDA margins initially comparable to Clorox and at least $50 million of expected run-rate cost synergies. The market will want those assumptions reaffirmed.
Household showed 3% Q3 sales growth, but some of that reflected shipments ahead of consumption in cat litter and grilling. Management expected slightly less than one percentage point of companywide shipment timing to reverse in Q4.
Fresh Step is the most important share-recovery test. Clorox changed product names, claims, packaging, pack sizes, pricing architecture and UPCs. Distribution increased, but shelf placement, out-of-stocks during conversion and weak early velocities complicated the rollout.
Investors should listen for:
Glad had been improving after sharper pricing, innovation and distribution gains. The tension in FY2027 is whether resin inflation forces price increases before the share recovery is firmly established.
Lifestyle sales fell 9% in Q3, with volume down 6%. Food-category consumption was weaker than management expected, competitors were discounting aggressively, and higher promotional spending hurt price/mix.
Hidden Valley had begun regaining share following:
A good result would show the business continuing to gain share despite a still-contracting category. A poor result would be continued double-digit segment sales pressure or profitability supported mainly by lower advertising.
Brita is another area to monitor because management had identified growing private-label pressure.
International was the strongest Q3 segment on a reported basis, with sales up 8%, organic sales up 2% and adjusted EBIT up 16%. Currency provided a material benefit, but volume was also positive.
Investors should distinguish:
Clorox shares closed July 31 at approximately $95.55, down roughly 23% from early August 2025. At that price, the stock trades around 17 times the midpoint of FY2026 adjusted-EPS guidance. The valuation is no longer demanding by Clorox’s historical standards, but the market is discounting weak organic growth, margin uncertainty, increased debt and execution risk.
The key FY2027 debate is whether earnings can begin normalizing as temporary items disappear.
The ideal outlook would pair positive organic growth with sequential gross-margin recovery and EPS growth. Guidance implying that cost inflation consumes most of the ERP and productivity benefits would likely disappoint.
On May 28, Clorox announced that Linda Rendle would step down as chair and CEO after a successor is appointed, citing health reasons. She remains in the role during the search. (investors.thecloroxcompany.com)
The company subsequently simplified its structure:
Investors should expect questions about:
The reorganization may improve accountability, but it also signals that execution has not been strong enough. Clear evidence of faster market-share recovery would validate the change.
The Q4 numbers have a low signal-to-noise ratio. ERP comparisons, GOJO acquisition accounting and energy inflation make the reported year-over-year declines look severe even if the underlying business is stabilizing.
The decisive issue is whether Clorox can demonstrate that FY2026 represents a trough. Investors should prioritize:
A clean quarter with positive share commentary and a credible FY2027 margin recovery could support a meaningful rebound from the stock’s depressed level. Another reset to expectations—particularly one caused by weak execution rather than external costs—would reinforce concerns that the recovery is being pushed further out.